Drugs / MAR001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT05896254 | Jul 2023 → Dec 2024 | hypertriglyceridemia | Marea Therapeutics | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT07199309 | Sep 2025 → Jul 2026 overdue | hypertriglyceridemia | Marea Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT07028749 | Jun 2025 → Jul 2026 overdue | hypertriglyceridemia | Marea Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-05-16 | Marea Therapeutics | Results Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease mareatx.com ↗
Results from Marea’s Phase 2a clinical trial of MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks with a favorable safety profile. |
| 2025-05-07 | Marea Therapeutics | Results Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress mareatx.com ↗
MAR001, a first-in-class monoclonal antibody targeting ANGPTL4, demonstrated approximately 53% placebo-adjusted mean reduction in remnant cholesterol and placebo-adjusted mean reduction in triglycerides at 12 weeks |
| 2025-01-09 | Marea Therapeutics | Results Marea Therapeutics Provides Update on Corporate Progress Including Positive Topline Results from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease and Disclosure of Second Lead Pipeline Program for the Treatment of Acromegaly mareatx.com ↗
Based on positive results from our Phase 2a study that demonstrate clinically meaningful reductions in remnant cholesterol and triglycerides, we are preparing to advance MAR001 into Phase 2b clinical development in the first half of 2025. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05896254 ↗ |
| Action | Inhibit | “ANGPTL4 inhibition with MAR001 can safely and effectively reduce circulating triglycerides and remnant cholesterol.” PMID 40383129 ↗ May 2025 |
| Route | Subcutaneous | “Subcutaneous Injection” NCT07028749 ↗ |
| Target | ANGPTL4 | “MAR001, an ANGPTL4 inhibitory antibody” PMID 40383129 ↗ May 2025 |